Securian Asset Management Inc. Has $1.63 Million Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Securian Asset Management Inc. cut its stake in DexCom, Inc. (NASDAQ:DXCM) by 5.0% during the fourth quarter, HoldingsChannel reports. The fund owned 20,992 shares of the medical device company’s stock after selling 1,096 shares during the quarter. Securian Asset Management Inc.’s holdings in DexCom were worth $1,633,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of DXCM. Versant Capital Management Inc acquired a new position in shares of DexCom in the fourth quarter worth $25,000. Private Trust Co. NA increased its position in DexCom by 266.3% during the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock worth $26,000 after buying an additional 245 shares during the last quarter. Larson Financial Group LLC increased its position in DexCom by 40.5% during the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock worth $37,000 after buying an additional 137 shares during the last quarter. Heck Capital Advisors LLC acquired a new position in DexCom during the fourth quarter worth $38,000. Finally, SBI Securities Co. Ltd. acquired a new position in DexCom during the fourth quarter worth $49,000. 97.75% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Morgan Stanley increased their target price on shares of DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research report on Friday, February 14th. Wells Fargo & Company reissued an “overweight” rating on shares of DexCom in a research report on Saturday, March 8th. Citigroup increased their target price on shares of DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a research report on Tuesday, March 4th. Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a report on Thursday, January 16th. Finally, Redburn Atlantic upgraded shares of DexCom from a “neutral” rating to a “buy” rating and upped their price target for the company from $85.00 to $115.00 in a report on Monday, February 3rd. Four investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $99.82.

DexCom Stock Down 3.2 %

NASDAQ DXCM opened at $68.48 on Friday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The firm has a 50-day simple moving average of $84.19 and a 200 day simple moving average of $76.87. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The stock has a market cap of $26.76 billion, a PE ratio of 47.89, a PEG ratio of 2.30 and a beta of 1.28.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, research analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

Insiders Place Their Bets

In other DexCom news, COO Jacob Steven Leach sold 2,634 shares of the firm’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $228,920.94. Following the completion of the transaction, the chief operating officer now owns 268,644 shares in the company, valued at $23,347,850.04. This trade represents a 0.97 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Kevin R. Sayer sold 33,359 shares of the firm’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the transaction, the chief executive officer now owns 319,037 shares of the company’s stock, valued at approximately $27,727,505.67. This represents a 9.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 45,083 shares of company stock worth $3,826,604 over the last quarter. Company insiders own 0.30% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.